Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Dysbiosis
Interventions: Goya Foods - Canned Chickpeas, Goya Foods - Canned Lentils, Control; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Rheumatoid Arthritis
Interventions: AZD9056, Etanercept, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Sunitinib, GM-CSF, Cyclophosphamide, IMA901; Drug · Biological
Lead sponsor: Immatics Biotechnologies GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID; Drug
Lead sponsor: TetraLogic Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Cleveland, Ohio + 2 more

Conditions: Retinoblastoma
Interventions: subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteer
Interventions: AVB-S6-500, Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Glioblastoma
Interventions: Bevacizumab, Onartuzumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection; Drug
Lead sponsor: Peter y. Liu; Other
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: VLBW - Very Low Birth Weight Infant
Interventions: Exempt Infant Formula; Other
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 168 Days to 224 Days
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Augusta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Tetraplegia, Asthma
Interventions: N-Nitro L-arginine-methylester (L-NAME); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Severe Sepsis, Acute Lung Injury
Interventions: High Dose Citrulline, Placebo, Low Dose Citrulline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Human Milk, Neonate, Breast Milk
Interventions: Targeted Fortification, The Miris Human Milk Analyzer; Dietary Supplement · Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: Up to 6 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Insulin Resistance
Interventions: Calorie Restriction, Control (normal living); Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non Small Cell Lung Cancer
Interventions: Stereotactic radiation therapy, Durvalumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 6 Years to 35 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 28 more

Conditions: Diet Modification
Interventions: Low glycemic index diet; Other
Lead sponsor: Sibylle Kranz, PhD, RDN; Other
Eligibility: 2 Years to 5 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: IXAZOMIB, Dexamethasone, Melphalan, Cyclophosphamide, Thalidomide, Lenalidomide; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Exenatide, Placebo, Metformin, Pioglitazone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 78
States / cities: Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 100
States / cities: Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more

Conditions: Hepatitis C
Interventions: GI-5005; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Pasadena, California • Denver, Colorado • Miami, Florida + 2 more

Conditions: Hypoxia, Hypercapnia
Interventions: L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hematologic Disease, Hemophilia A
Interventions: Kogenate (BAY14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 30 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas

Conditions: Chondral Defect, Articular Cartilage Defect
Interventions: autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 17 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Sacramento, California • Washington D.C., District of Columbia • Wichita, Kansas + 6 more

Search by objective public record fields.

Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

A Phase 1 AVB-S6-500 Safety and Tolerability Study

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Hormonal Mechanisms of Sleep Restriction - Axis Study

Feeding Study in VLBW Premature Infants

Exhaled Levels of Nitric Oxide

Citrulline in Severe Sepsis

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Increasing Lean Protein Intake in Preschool-age Children and Assessing Effects on Cognition and Select Health Outcomes

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

A Study in Participants With Type 2 Diabetes Mellitus

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle